NCT02141542View on ClinicalTrials.gov

Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

September 23, 2020

Study Completion Date

September 23, 2020

Conditions
Metastatic Melanoma
Interventions
DRUG

Tremelimumab

DRUG

MEDI3617

Trial Locations (2)

02115

Dana Farber Cancer Institute, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors

Collaborators (1)

MedImmune LLC
All Listed Sponsors
collaborator

MedImmune LLC

INDUSTRY

lead

F. Stephen Hodi, MD

OTHER

NCT02141542 - Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma | Biotech Hunter | Biotech Hunter